CoChat

Interaction of Approved Drugs with Synaptic Vesicle Protein 2A

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

Levetiracetam (LEV) and its recently approved derivative brivaracetam are anti‐epileptic drugs with a unique mechanism of action. The synaptic vesicle protein 2A (SV2A) was previously identified as their main target. In the current study, we tested a collection of 500 approved drugs for interaction with the human SV2A protein expressed in Chinese hamster ovary cells. Competition binding studies were performed using cell lysates with high SV2A expression and [3 H]brivaracetam as a radioligand. A hit rate of 3% was obtained, defined as compounds that inhibited radioligand binding by more than 90% at a screening concentration of 20 μM. Subsequent concentration–inhibition curves revealed the antihistaminic prodrug loratadine (Ki = 1.16 μM) and the antimalarial drug quinine (Ki = 2.03 μM) to be the most potent SV2A protein ligands of the investigated drug library. Both compounds were similarly potent as LEV (Ki = 1.74 μM), providing structurally novel scaffolds for SV2A ligands. A pharmacophore model was established, which indicated steric and electronic conformities of brivaracetam with the new SV2A ligands, and preliminary structure–activity relationships were determined. The anti‐convulsive effects of the natural product quinine may – at least in part – be explained by interaction with SV2A. Loratadine and quinine represent new lead structures for anti‐epileptic drug development.

Overview

Integrity signals

Registry

Crossref · 10.1002/ardp.201700003

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Research works printed but not linked: 5

  1. Kaminski R. M., 2012, Jaspers Basic Mechanisms of the Epilepsies
  2. S.Hildenbrand Ph.D. Thesis University of Bonn 2012.
  3. Clifford M., 2012, Ann. Neurosci, 19, 14
  4. Etemadi F., 2016, Iran. Biomed. J, 20, 266
  5. 10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P · DOI · Paper page

Cited by

See all 20

Metadata

Authors
Danish, A., Namasivayam, V., Schiedel, A. C., & Müller, C. E.
Affiliations
University of Bonn (DE)
Corresponding author
Müller, Christa E.
Venue
Archiv der Pharmazie
Publisher
Wiley
Published
2017-02-21
Volume
350
Issue
3-4
ISSN
  • 0365-6233 (ISSN-L)
  • 1521-4184
OpenAlex
W2589165737
Cited by
19
References
45
Citations by year
2026: 1 · 2025: 3 · 2024: 6 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 1 · 2018: 1 · 2017: 1
FWCI
1.12
Type
journal article
Language
en
Open access
closed
Locations
  • Archiv der Pharmazie (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Keywords
SV2A, levetiracetam, brivaracetam, drug repurposing, approved drugs, loratadine, quinine, anticonvulsant mechanism, pharmacophore model, structure-activity relationship, radioligand binding
MeSH terms
Levetiracetam, Animals, Anticonvulsants, Cricetulus, Dose-Response Relationship, Drug, Humans, Ligands, Membrane Glycoproteins, Nerve Tissue Proteins, Piracetam, Pyrrolidinones, Quinine, Structure-Activity Relationship, Molecular Structure, CHO Cells, Loratadine

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interaction of Approved Drugs with Synaptic Vesicle Protein 2A. https://app.cochat.ai/papers/10.1002/ardp.201700003
The paper
Danish, A., Namasivayam, V., Schiedel, A. C., & Müller, C. E. (2017). Interaction of Approved Drugs with Synaptic Vesicle Protein 2A. Archiv der Pharmazie. https://doi.org/10.1002/ardp.201700003

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.